U.S. pharma large copyright scrapped two experimental weight loss tablets past calendar year—a at the time-day by day capsule, lotiglipron, due to elevated liver enzymes in addition to a 2 times-everyday capsule, danuglipron, resulting from potent Unintended effects—but CEO Albert Bourla has explained the company is set to “play and acquire�